JMP Securities analyst Jason Butler reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) today and set a price target of $15.00. The company’s shares opened today at $1.95.
According to TipRanks, Butler is an analyst with an average return of -10.4% and a 35.86% success rate. Butler covers the Healthcare sector, focusing on stocks such as Cytokinetics, Aquestive Therapeutics, and Minerva Neurosciences.
Currently, the analyst consensus on Quoin Pharmaceuticals is a Strong Buy with an average price target of $15.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $94.00 and a one-year low of $1.57. Currently, Quoin Pharmaceuticals has an average volume of 1.59M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Read More on QNRX:
- Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
- Quoin Pharma Pops After Plans to Start a Second Clinical Trial
- Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
- Quoin announces plans to initiate second trial in Netherton syndrome patients
- Quoin Pharmaceuticals establishes patient specific website for ongoing study
